Glycom is a biotechnology company with locations in Hørsholm and in Esbjerg, Denmark. We focus on the development, synthesis and commercialization of human milk oligosaccharides (HMOs). HMOs are a group of oligosaccharides which are present in high concentrations in human milk and contribute to many of the wonderful health benefits of mothers milk. In particular, they modulate the infant’s intestinal microbiota to promote the growth of beneficial bacteria and reduce pathogens, protect the infant against infections, and promote development of the infant’s intestine and immune system. HMOs are also believed to contribute to the development of the infant’s brain. They may also be extremely beneficial to older children and adults.
Previously commercial use of HMOs has been blocked by lack of availability and high cost. Our breakthrough technologies are changing this paradigm permanently. We have developed efficient microbial fermentation, chemical and enzymatic technologies allowing us to synthesize HMOs. The lead HMOs in our pipeline have robust production technologies now entering industrialisation and we have produced them on large scale under GMP conditions.
We and our partners have conducted large, randomized, controlled clinical studies showing safety and tolerance in infants and adults and impact on microbiota. Also, our lead HMOs have been approved for use in foods in Europe and the US. We also have a rich pipeline of other HMOs in early stages of development. We have an active pre-clinical and clinical program to investigate and prove the beneficial properties of HMOs.
We are currently expanding our team in production and process development in Esbjerg and R&D in Hørsholm so check out our openings!
